Sensimed Raises CHF17M in First Close of Series C Funding

Sensimed AG, a Swiss company that develops a non-invasive soft contact lens-based solution to help treat glaucoma, has raised CHF 17m in the first close of its Series C funding.

The round was co-led by Wellington Partners, Agate Medical Investments and Vinci Capital/Renaissance PME, with participation from Sandoz Family Foundation and ELM Development.

The company intends to use the capital to finalize approval in the US and in China, to extend the commercialization currently restricted to leading centers in about twenty countries to a larger geography, to continue a wide-spectrum of post-marketing application trials, to implement and open the central registry to all users, and to fund on-going operations.

Led by CEO Jean-Marc Wismer, Sensimed has developed a non-invasive soft contact lens-based solution, called the SENSIMED Triggerfish(R), that provides continuous 24-hour intraocular pressure (IOP) profiles as well as modeling and analysis of IOP patterns. The 24-hour IOP profiles, centralized on a registry together with patient and treatment information, are processed by modeling and learning algorithms identifying pathological patterns that can be used to differentiate indication and to personalize treatment.



Join the discussion